Information of abbreviation data set (5).docx

The efficacy of nefopam, a non-opioid, non-steroidal, central acting drug, for cancer pain remains unclear. We evaluated the analgesic efficacy of nefopam for cancer pain. Patients with moderate to severe cancer pain (n=40) were randomly divided into two groups. The nefopam group (n=20) received three 20 mg doses of nefopam every 8 hours. The placebo group (n=20) received normal saline. Intravenous patient-controlled analgesia with morphine was given for breakthrough pain for 48 hours. The primary outcome was significant pain reduction. Secondary outcomes were morphine consumption over 48 hours and incidence of side effects.<br>Article relating to this data published on F1000Research: DOI 10.12688/f1000research.23455.1.<br>